MK-1654 en lactantes y niños con mayor riesgo de enfermedad grave por el virus respiratorio sincicial
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).